ATG2B and breast cancer: Altogether, these data strongly showed that our BC signature using the systematic quantification of ATG2B, BECN1, LC3B, ATG5, and eventually ULK1 and IRF1 led to a robust discrimination of BC subgroups and helped for prognosis.